Bis zu 90% sparen! Kostenloser Depotgebühren-Check
030-275 77 6400
DAX+1,31 % EUR/USD-0,02 % Gold-0,59 % Öl (Brent)0,00 %

Mauna Kea Technologies Announces Reimbursement Coverage in France for the Use of Confocal Laser Endomicroscopy for Barrett’s Esophagus

Nachrichtenquelle: Business Wire (engl.)
17.06.2019, 18:02  |  931   |   |   

Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, announced the reimbursement coverage of confocal laser endomicroscopy, specifically for Barrett’s esophagus, through the creation of a new specific procedural code to be added to the Common Classification of Medical Procedures (CCAM) published in the Official Journal of the French Republic.

In a decision dated April 18th 2019 and published in the Official Journal on June 14th 2019, the French National Association of Health Insurance Funds (UNCAM) created the following procedure, in sub-paragraph “ - Endoscopy of the salivary glands and digestive tract” of Book II of the Social Security Code: “Esophageal endoscopy with confocal laser endomicroscopy-guided biopsy - Pre-therapeutic esophageal mapping with biopsy guided by confocal laser endomicroscopy” 1. The tariffs reimbursed are as follows: 150 euros for the endoscopist (Activity 1) and 69 euros for anesthesia (Activity 4). This UNCAM’s decision will take effect 30 days after its publication.

"We are pleased with the decision of the “Union Nationale des Caisses d’Assurance Maladie”, or UNCAM, to create a new code dedicated to esophageal procedures with Confocal Laser Endomicroscopy,” said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies. “This decision confirms the relevance of our technology for patients at risk of esophageal cancer and we look forward to expanding our unique probe-based Confocal Laser Endomicroscopy system, Cellvizio, to the more than 300 hospitals throughout France that specialize in following patients with Barrett’s esophagus.”

Mr. Gershon continued: “There are more than 45,000 esophagogastroduodenoscopy procedures in France each year that potentially can be performed with Cellvizio going forward. Importantly, now clinicians performing these procedures will all be eligible for reimbursement at an attractive rate. Thanks to the creation of this new procedural code, the French market - a market in which we already enjoy a strong reputation - is finally available to Mauna Kea for broad-commercialization of our Cellvizio technology.”

Diesen Artikel teilen
Seite 1 von 3
Mehr zum Thema

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors


Diskussionen zu den Werten